News | December 16, 2010

Customized Solutions Meet the Demands of an Evolving Radiology Market

Customized Solutions Meet the Demands of an Evolving Radiology Market

December 16, 2010 – Bracco Imaging demonstrated how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at the Radiological Society of North America (RSNA) meeting. The company is also showing regulatory progress related to its contrast media in computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine, cardiac catheterization, interventional/diagnostic radiology and its contrast delivery systems.

“A number of factors are shaping the evolution of radiology today, including rapid innovation, cost control and an acute awareness of product safety,” said Carlo Medici, head of global commercial operations of Bracco Imaging and president and CEO, Bracco Diagnostics.

The company’s Isovue (iopamidol injection) is available in a convenient range of iodine concentrations and packaging options, making it the top osmolar contrast media agent in the United States.

The company also continues to see robust growth stemming from its 2008 acquisition of E-Z-EM, one of the most recognized brands among radiologists and gastrointestinal (GI) physicians. Among these are the company’s injector and data management systems, which enable radiologists, administrators and technologists to gain workflow efficiencies, imaging optimization and patient safety benefits. Also, through this acquisition, Bracco is now the only provider of barium-based oral imaging products.

Safety, Efficacy and Efficiency in MRI

The company’s gadolinium-based contrast agents (GBCAs) - MultiHance (gadobenate dimeglumine) and ProHance (gadoteridol) - are increasingly the MRI agents of choice by radiologists in more than 2,000 healthcare facilities in the United States.

MultiHance was the first and only contrast agent approved for MRI of the central nervous system (CNS) in the United States, with twice the relaxivity compared to other tested extracellular contrast agents. This means greater contrast-to-noise and lesion-to-brain ratio, which may lead to improved visualization. ProHance is the only macrocyclic gadolinium contrast agent available in the United States, with an exceptionally stable Gd chelate.

Nephrogenic systemic fibrosis (NSF), a rare and potentially life threatening syndrome in patients with renal impairment, has been associated with GBCAs. This has fueled significant clinical and scientific activity in attempts to determine the etiology of this disease. In response the U.S. Food and Drug Administration (FDA) recently published new guidelines defining specific classes of GBCAs based on risk of causing NSF. In a briefing document dated December 8, 2009, the FDA wrote: “Of the 5 GBCs considered, the higher risk is associated with Omniscan, Magnevist, and OptiMARK while the lowest risk is associated with ProHance and MultiHance.”

Further, the American College of Radiology that radiologists should administer GBCAs to renally impaired patients only where necessary. The ACR also advised using the lowest possible dose.

Studies demonstrate that MultiHance provides significantly greater diagnostic information and lesion visualization when compared to two other commonly used contrast agents used at an equivalent dose. It is also FDA-approved for intravenous use in MRI of the CNS in children over two years of age.

For more information: usa.braccoimaging.com

Related Content

Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co